Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Total Liabilities (2021 - 2025)

Amylyx Pharmaceuticals has reported Total Liabilities over the past 5 years, most recently at $27.4 million for Q4 2025.

  • Quarterly results put Total Liabilities at $27.4 million for Q4 2025, down 5.14% from a year ago — trailing twelve months through Dec 2025 was $27.4 million (down 5.14% YoY), and the annual figure for FY2025 was $27.4 million, down 5.14%.
  • Total Liabilities for Q4 2025 was $27.4 million at Amylyx Pharmaceuticals, down from $30.7 million in the prior quarter.
  • Over the last five years, Total Liabilities for AMLX hit a ceiling of $124.1 million in Q3 2021 and a floor of $17.4 million in Q4 2021.
  • Median Total Liabilities over the past 5 years was $49.5 million (2022), compared with a mean of $54.2 million.
  • Biggest five-year swings in Total Liabilities: surged 191.7% in 2022 and later tumbled 80.37% in 2025.
  • Amylyx Pharmaceuticals' Total Liabilities stood at $17.4 million in 2021, then soared by 191.7% to $50.8 million in 2022, then soared by 65.25% to $84.0 million in 2023, then crashed by 65.64% to $28.9 million in 2024, then decreased by 5.14% to $27.4 million in 2025.
  • The last three reported values for Total Liabilities were $27.4 million (Q4 2025), $30.7 million (Q3 2025), and $26.7 million (Q2 2025) per Business Quant data.